Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eyenovia, Inc. stock logo
EYEN
Eyenovia
$15.96
+51.1%
$3.99
$0.85
$124.80
$45.97M2.471.26 million shs4.63 million shs
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
$0.55
-0.2%
$0.55
$0.22
$1.97
$30.32M1.031.84 million shs260 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shs300 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.54
+1.2%
$0.65
$0.46
$4.19
$30.92M-0.02831,297 shs112,613 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eyenovia, Inc. stock logo
EYEN
Eyenovia
0.00%+46.69%+227.05%+1,616.68%-77.12%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
0.00%0.00%0.00%0.00%-54.24%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%0.00%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
0.00%-2.54%-3.93%-51.96%-85.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eyenovia, Inc. stock logo
EYEN
Eyenovia
2.6195 of 5 stars
3.05.00.00.03.00.00.6
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
2.3188 of 5 stars
3.20.00.04.20.61.70.6
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
1.4911 of 5 stars
3.51.00.00.00.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eyenovia, Inc. stock logo
EYEN
Eyenovia
2.00
Hold$2.00-87.47% Downside
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
2.40
Hold$3.92613.29% Upside
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.00
Buy$7.331,263.07% Upside

Current Analyst Ratings Breakdown

Latest OBSV, RANI, EYEN, and MRNS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eyenovia, Inc. stock logo
EYEN
Eyenovia
$60K766.08N/AN/A($695.52) per share-0.02
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
$30.99M0.98N/AN/A$0.31 per share1.77
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$1.03M30.02N/AN/A$0.06 per share8.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eyenovia, Inc. stock logo
EYEN
Eyenovia
-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$30.02M-$0.99N/AN/AN/AN/A-1,258.76%-80.52%8/5/2025 (Estimated)

Latest OBSV, RANI, EYEN, and MRNS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q1 2025
Eyenovia, Inc. stock logo
EYEN
Eyenovia
-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million
5/13/2025Q1 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.22-$0.22N/A-$0.22N/A$0.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eyenovia, Inc. stock logo
EYEN
Eyenovia
N/AN/AN/AN/AN/A
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eyenovia, Inc. stock logo
EYEN
Eyenovia
N/A
0.34
0.34
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
N/A
1.66
1.47
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.75
0.88
0.88

Institutional Ownership

CompanyInstitutional Ownership
Eyenovia, Inc. stock logo
EYEN
Eyenovia
25.84%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
98.80%
ObsEva SA stock logo
OBSV
ObsEva
17.52%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%

Insider Ownership

CompanyInsider Ownership
Eyenovia, Inc. stock logo
EYEN
Eyenovia
7.10%
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
5.46%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
53.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eyenovia, Inc. stock logo
EYEN
Eyenovia
402.88 million2.68 millionOptionable
Marinus Pharmaceuticals, Inc. stock logo
MRNS
Marinus Pharmaceuticals
11055.22 million52.20 millionOptionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
11057.48 million26.84 millionOptionable

Recent News About These Companies

Rani Therapeutics strikes deal to issue new warrants
RANI: 1Q:25 Financial Results
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)
Rani Therapeutics management to meet virtually with Lake Street
RANI: 2024 Financial Results
Q4 2024 Rani Therapeutics Holdings Inc Earnings Call
Rani Therapeutics reports Q4 EPS (27c), consensus (23c)
An Overview of Rani Therapeutics Hldgs's Earnings
Rani announces pharmacokinetic, pharmacodynamic data from RT-114 trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eyenovia stock logo

Eyenovia NASDAQ:EYEN

$15.96 +5.40 (+51.14%)
Closing price 07/2/2025
Extended Trading
$15.96 0.00 (0.00%)
As of 07/2/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Marinus Pharmaceuticals stock logo

Marinus Pharmaceuticals NASDAQ:MRNS

$0.55 0.00 (-0.16%)
As of 02/11/2025

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Rani Therapeutics stock logo

Rani Therapeutics NASDAQ:RANI

$0.54 +0.01 (+1.17%)
Closing price 07/3/2025 03:53 PM Eastern
Extended Trading
$0.54 0.00 (0.00%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.